Repatha Cost in New Jersey 2026: Price, Insurance, Medicaid, and Compounding Options

Evolocumab, sold under the brand name Repatha (Amgen), is a fully human monoclonal antibody that blocks PCSK9, a liver protein that otherwise degrades LDL receptors. The FDA approved it in 2015 for adults with heterozygous or homozygous familial hypercholesterolemia and for people with established atherosclerotic cardiovascular disease who need further LDL-lowering beyond a maximally tolerated statin (per FDA prescribing information). It is given as a subcutaneous injection, either 140 mg every two weeks or 420 mg once monthly, and it is not the same molecule as alirocumab (Praluent) or inclisiran (Leqvio), two other LDL-lowering agents that work differently and carry separate FDA approvals and pricing.

The most useful framing for a New Jersey patient is not "what does Repatha cost" but "which payer pathway applies to me." List price, insurance status, and program eligibility interact so strongly that the same drug can cost a patient $0 a month or several thousand dollars a year, and the answer depends on documentation and enrollment steps rather than on the drug itself. Federal and state program structures (Medicaid rebate rules, FDA approval status, New Jersey's step-therapy override law) are stable and can be cited with confidence. Specific dollar figures, plan-level prior-authorization criteria, and pharmacy cash prices change often enough that they need to be reverified at the point of care rather than taken from any single article, including this one.

What is actually stable, and what changes

Evolocumab's FDA-approved indications, its mechanism, and the existence of manufacturer and Medicaid support structures are not likely to change quickly. What does change, often within months, is the exact prior-authorization checklist a given New Jersey Medicaid managed care organization or commercial plan uses, the size of manufacturer copay assistance, and cash prices at individual pharmacies. Treat any specific number in this article as a starting point for verification, not a quote to give a patient.

Brand-name list price

Reporting on PCSK9 inhibitor pricing has generally placed Repatha's monthly list price in the range of roughly $500 to $600, but the exact current wholesale acquisition cost and the exact cash price at a specific New Jersey pharmacy both change over time and by location. Before telling a patient what they will pay in cash, confirm the current price directly with Amgen (https://www.repatha.com/) or with the dispensing pharmacy. There is no New Jersey-specific price control on this branded biologic outside of the federal Medicaid drug rebate program (https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html).

New Jersey Medicaid (NJ FamilyCare)

NJ FamilyCare, like Medicaid programs generally, uses prior authorization for specialty biologics such as evolocumab (general Medicaid PA framework: https://www.medicaid.gov/medicaid/prescription-drugs/prior-authorization/index.html). Typical PA criteria for PCSK9 inhibitors across Medicaid programs require documentation of familial hypercholesterolemia or established atherosclerotic cardiovascular disease, plus evidence that the patient has tried a high-intensity statin and often ezetimibe. The specific criteria, review timelines, and appeal steps used by an individual NJ FamilyCare managed care organization can differ from plan to plan and should be pulled from that plan's current provider portal rather than assumed. Medicaid enrollees generally face nominal cost-sharing per Kaiser Family Foundation's national summary of Medicaid prescription drug benefits, but the exact copay amount is state- and plan-specific and should be confirmed against the current NJ FamilyCare benefit schedule.

If a prior authorization is denied, New Jersey allows appeal through the plan and, if unsuccessful, escalation to an Independent Utilization Review Organization under state insurance regulation. New Jersey also has a step-therapy override statute that requires insurers to provide an exception process when step therapy is clinically inappropriate; the National Conference of State Legislatures tracks state step-therapy laws generally (https://www.ncsl.org/health/step-therapy-state-laws). The specific override timeline for New Jersey should be verified against the current statute text rather than assumed from a secondary summary.

Commercial insurance and the Amgen savings card

Most commercial plans sold in New Jersey, including marketplace plans, place evolocumab on a specialty tier with prior authorization criteria similar to Medicaid's. Amgen offers a manufacturer copay assistance program for commercially insured patients who are not enrolled in a government payer (Medicare, Medicaid, TRICARE, or VA); program terms, eligibility, and the maximum benefit are described on Amgen's own site (https://www.repatha.com/) and should be confirmed there directly, since manufacturer copay program terms change periodically. Patients on Medicare Part D generally cannot use manufacturer copay cards under federal anti-kickback rules; Medicare Part D cost-sharing structure and the effect of recent Inflation Reduction Act changes are described in general terms by policy research organizations, but plan-specific out-of-pocket amounts vary and require plan-level lookup.

Whether a manufacturer coupon counts toward a patient's deductible depends on whether a plan applies a "copay accumulator" adjustment. New Jersey did not have an active accumulator-blocking law prohibiting this practice as of the source review date; this is exactly the kind of rule that can change and should be reconfirmed with the New Jersey Department of Banking and Insurance before advising a patient.

Compounded evolocumab: treat with real caution

This is the point in the article that needs the most editorial scrutiny. Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacists to compound a patient-specific preparation when a commercially available FDA-approved product does not meet a documented clinical need, such as a genuine excipient allergy (503A framework: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities; FDA guidance touching biological product compounding). Cost alone is not a recognized justification for 503A compounding when an FDA-approved product exists.

Evolocumab is not a small peptide; it is a large monoclonal antibody biologic manufactured under a Biologics License Application, and routine retail pharmacy compounding of monoclonal antibodies is not an established, widespread practice in the way that compounding of some small-molecule or peptide drugs is. A claim that multiple New Jersey 503A pharmacies routinely compound evolocumab at $75 to $200 a month has not been verified against a primary regulatory or clinical source for this draft, and it should not be presented to readers as an established option. If a pharmacy represents that it compounds evolocumab, a patient or clinician should independently confirm that pharmacy's current license status through the New Jersey Board of Pharmacy's verification tool (https://www.njconsumeraffairs.gov/phar/Pages/Verify-a-License.aspx), ask what specific clinical justification supports compounding rather than dispensing the FDA-approved product, and understand that no clinical trial evidence of cardiovascular benefit exists for a compounded version. The trials that established evolocumab's cardiovascular benefit used the branded, FDA-approved product; a compounded preparation has not been shown to have the same bioavailability, immunogenicity profile, or outcomes data.

Telehealth prescribing

New Jersey permits telehealth-initiated prescribing by licensed New Jersey providers under the state's telemedicine statute, which requires a synchronous encounter, a valid New Jersey license for the prescriber, and the patient's physical presence in New Jersey at the time of the visit (https://www.njleg.state.nj.us/Bills/2016/PL17/117_.PDF). Documentation requirements for evolocumab, such as a qualifying diagnosis and recent lipid panel, are the same whether the visit is in-person or via telehealth.

What the underlying trial evidence supports, in general terms

Evolocumab's approval rests on trial evidence showing substantial LDL-C lowering and a reduction in cardiovascular events when added to statin therapy in people with established atherosclerotic disease, and on separate trial evidence in familial hypercholesterolemia. The specific percentage reductions and hazard ratios often cited for these trials (commonly referred to by name, including FOURIER and GLAGOV) are widely reported in cardiology literature, but the exact figures should be checked against the original published trial report before being quoted to a patient, since secondary summaries sometimes carry rounding errors or misattributed numbers. This article deliberately does not restate specific percentage or hazard-ratio figures without that verification step, because an exact number stated with false confidence is a more serious problem than a general statement.

Guideline bodies including the ACC/AHA have positioned PCSK9 inhibitors as an option for patients with established cardiovascular disease or familial hypercholesterolemia who remain above LDL-C goals on maximally tolerated statin therapy, generally after statin and ezetimibe have been tried. The current, exact guideline language and class-of-recommendation wording should be pulled from the live guideline document rather than a paraphrase, since focused updates have revised specific thresholds over time.

Evidence boundary

Established: Evolocumab is FDA-approved for specific hyperlipidemia and cardiovascular indications; it works by inhibiting PCSK9; New Jersey Medicaid and most commercial insurers require prior authorization for specialty PCSK9 inhibitors; New Jersey permits telehealth prescribing under state law; manufacturer copay assistance programs and Medicaid drug rebate structures exist federally.

Plausible but requiring plan-specific verification: Exact prior-authorization criteria and turnaround times at any individual New Jersey Medicaid MCO or commercial plan; the exact current cash price at a given New Jersey pharmacy; whether a specific plan applies a copay accumulator to the Amgen card.

Not established from the material reviewed for this draft: That compounded evolocumab is a routine, legally straightforward, or clinically validated option through New Jersey 503A pharmacies at a specific price point. That claim needs primary verification (a specific pharmacy's compliance history, an FDA statement specific to monoclonal antibody compounding, and confirmation of the clinical-need documentation actually used) before it should be repeated to readers as a viable cost-saving pathway.

When to seek care or advice beyond this article

A patient should talk to their prescriber, not rely on cost information alone, if they experience injection-site reactions that worsen or spread, signs of an allergic reaction (hives, facial swelling, difficulty breathing), or if they are considering stopping the medication because of cost before exploring assistance programs, since abrupt discontinuation removes the LDL-lowering effect the medication was prescribed to achieve. Anyone offered a compounded version of a biologic drug from a source that cannot produce a current pharmacy license and a specific documented clinical justification should treat that offer with skepticism and raise it with their prescriber before use.

Verification checklist: stable facts vs. facts that expire

Use this before quoting any figure from this article to a patient.

Stable federal and clinical facts (safe to state without a date caveat):

• Evolocumab is FDA-approved and works by inhibiting PCSK9 (FDA label).
• It is a monoclonal antibody biologic, distinct from alirocumab (Praluent) and inclisiran (Leqvio).
• Federal 503A compounding law does not permit compounding solely to reduce cost when an FDA-approved product exists and no documented patient-specific need applies.
• Medicare Part D enrollees generally cannot use manufacturer copay cards.
• New Jersey has a telemedicine statute permitting remote prescribing under specified conditions.

Facts that must be reverified before each use because they change (confirm the date and source each time):

• Current list price and cash price at a specific New Jersey pharmacy.
• The specific NJ FamilyCare MCO's current prior-authorization criteria and appeal timeline.
• Amgen savings card eligibility terms and maximum benefit amount.
• Whether a specific New Jersey commercial plan applies a copay accumulator.
• Whether any specific pharmacy claiming to compound evolocumab currently holds an active, unrestricted New Jersey pharmacy license (check directly at the Board of Pharmacy verification tool) and what documented clinical justification, if any, supports that compounding.
• Current guideline wording and class-of-recommendation language for PCSK9 inhibitors, since focused updates revise thresholds over time.

If a number in this checklist's second category cannot be confirmed from a current primary source at the time of use, state the uncertainty to the patient rather than repeating an older figure as current fact.